drugset / Trial / NCT04617509
A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
Phase 1
Completed
14 enrolled
Gesynta Pharma AB
CTC Clinical Trial Consultants AB · collabResearch Institutes of Sweden · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The study will collect information about pharmacokinetics (PK), safety and tolerability following a single dose of GS-248 in two different oral solid formulations in capsules to healthy subjects. It will also collect information about pharmacokinetics (PK), safety and tolerability following a single dose of one of the two formulations of GS-248 in fed condition.
Timeline
- Start
- 2020-03-31
- Primary completion
- 2020-05-27
- Completion
- 2020-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vipoglanstat | Small molecule | 120 mg | Oral |
Indications
No indication recorded.